Tissue & Advanced Therapies Research
The FDA has updated its informational resource regarding research activities conducted within the field of tissue and advanced therapies.
Manufacturers and developers of tissue-based products, cellular therapies, and gene therapy medicinal products.
Ongoing FDA research in advanced therapies often signals the agency's current scientific focus areas and potential future areas of regulatory scrutiny. This activity suggest that CBER is prioritizing the development of scientific frameworks to evaluate the safety and efficacy profiles of these complex biologics.
Regulatory and R&D teams should monitor CBER’s research portfolio updates to identify potential alignment with their own developmental pipelines. Compliance officers may want to ensure that internal data standards reflect the scientific priorities currently emphasized by the Center.
This page is about Tissue & Advanced Therapies Research
Open in openFDA / FDA.gov